GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: L/105 | Rifamycin L 105 | Xifaxan®
rifaximin is an approved drug (FDA (2004))
Compound class:
Synthetic organic
Comment: Rifaximin is a semisynthetic derivative of rifamycin and belongs to the ansamycin group of antibacterial compounds [1]. It has broad spectrum activity against Gram-positive and Gram-negative bacteria.
|
|
|||||||||||||||||||||||||||||||||||
Classification ![]() |
|
| Compound class | Synthetic organic |
| Approved drug? | Yes. US FDA (2004) |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 5244 | rifaximin |
Synonyms ![]() |
| L/105 | Rifamycin L 105 | Xifaxan® |
Database Links ![]() |
|
| Specialist databases | |
Antibiotic DB
|
Rifaximin |
| Other databases | |
| CAS Registry No. | 80621-81-4 (source: Scifinder) |
| ChEBI | CHEBI:75246 |
| ChEMBL Ligand | CHEMBL1617 |
| DrugBank Ligand | DB01220 |
| GtoPdb PubChem SID | 464244153 |
| PubChem CID | 6436173 |
| RCSB PDB Ligand | RXM |
| Search Google for chemical match using the InChIKey | NZCRJKRKKOLAOJ-XRCRFVBUSA-N |
| Search Google for chemicals with the same backbone | NZCRJKRKKOLAOJ |
| Search PubMed clinical trials | rifaximin |
| Search PubMed titles | rifaximin |
| Search PubMed titles/abstracts | rifaximin |
| UniChem Compound Search for chemical match using the InChIKey | NZCRJKRKKOLAOJ-XRCRFVBUSA-N |
| UniChem Connectivity Search for chemical match using the InChIKey | NZCRJKRKKOLAOJ-XRCRFVBUSA-N |
| Wikipedia | Rifaximin |
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.
✖